On Friday, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) opened lower -2.17% from the last session, before settling in for the closing price of $9.67. Price fluctuations for SNDX have ranged from $8.58 to $25.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -15.16% over the last five years. Company’s average yearly earnings per share was noted -2.31% at the time writing. With a float of $82.47 million, this company’s outstanding shares have now reached $86.05 million.
The firm has a total of 270 workers. Let’s measure their productivity. In terms of profitability, gross margin is -3.44%, operating margin of -786.59%, and the pretax margin is -757.52%.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Syndax Pharmaceuticals Inc is 4.16%, while institutional ownership is 115.58%. The most recent insider transaction that took place on Jul 16 ’25, was worth 12,033. In this transaction Chief Financial Officer of this company sold 1,296 shares at a rate of $9.29, taking the stock ownership to the 92,450 shares. Before that another transaction happened on Jul 16 ’25, when Company’s Chief Executive Officer sold 7,534 for $9.29, making the entire transaction worth $69,953. This insider now owns 298,661 shares in total.
Syndax Pharmaceuticals Inc (SNDX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -2.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.93% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Check out the current performance indicators for Syndax Pharmaceuticals Inc (SNDX). In the past quarter, the stock posted a quick ratio of 5.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.87, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -2.75 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Analysing the last 5-days average volume posted by the [Syndax Pharmaceuticals Inc, SNDX], we can find that recorded value of 1.61 million was lower than the volume posted last year of 2.17 million. As of the previous 9 days, the stock’s Stochastic %D was 59.73%.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 11.11%, which indicates a significant decrease from 60.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.56 in the past 14 days, which was lower than the 0.77 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.93, while its 200-day Moving Average is $13.82. Now, the first resistance to watch is $9.78. This is followed by the second major resistance level at $10.11. The third major resistance level sits at $10.36. If the price goes on to break the first support level at $9.20, it is likely to go to the next support level at $8.95. Should the price break the second support level, the third support level stands at $8.62.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
There are currently 86,047K shares outstanding in the company with a market cap of 814.01 million. Presently, the company’s annual sales total 23,680 K according to its annual income of -318,760 K. Last quarter, the company’s sales amounted to 20,040 K and its income totaled -84,850 K.
